Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

1. 5. 5		
Name	of entity	
MAC	CMAHON HOLDINGS LIMITED	
ABN		
93 00	07 634 406	
We (1	the entity) give ASX the followin	g information.
`	17.8	O
Part	: 1 - All issues	
	ust complete the relevant sections (attac	ch sheets if there is not enough space).
	,	<i>3 1</i> ,
1	*Class of *securities issued or to	Performance Rights
	be issued	
	Nil	
2	Number of *securities issued or to be issued (if known) or	361,727
	maximum number which may	
	be issued	

⁺ See chapter 19 for defined terms.

Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if +securities, partly paid the amount outstanding and due dates for payment; if securities, +convertible the conversion price and dates for conversion)

The Performance Rights are granted pursuant to the terms of the company's Executive Equity Plan dated on July 2017.

Performance Rights will be eligible to vest into fully paid ordinary shares on the third anniversary of 1 July 2018:

- (a) provided the recipient of the Performance Right is still an employee of the Macmahon group on that date; and
- (b) to an extent dependent upon the compound annual growth rate ("CAGR") in Macmahon's total shareholder return ("TSR") over the three year period from 1 July 2018 to 1 July 2021 (the "Performance Period").

The extent to which growth in TSR over the Performance Period will result in the vesting of Performance Rights is set out in the following table:

Macmahon's absolute TSR performance over the Performance Period	Proportion of TSR Share performance rights that are eligible to vest
Less than a 17% CAGR in TSR	ο%
17% CAGR in TSR	50%
Between 17% and 25% CAGR in TSR	50% plus a straight line increase in % award until Target TSR is achieved.
At 25% or more CAGR in TSR	100%

No amount is payable upon the issue or vesting of Performance Rights.

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

No - Performance rights are not quoted securities, and do not confer the right to vote or participate in dividends or distributions.

If the additional *securities do not rank equally, please state:

If and when a Performance Right vests, the resulting fully paid ordinary share will rank equally with all then issued ordinary shares.

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

Nil

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Performance rights are granted as equity compensation benefits to certain senior executives pursuant to the company's Executive Equity Plan dated on July 2017.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

N/A

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

N/A

6c Number of *securities issued without security holder approval under rule 7.1

N/A

6d Number of *securities issued with security holder approval under rule 7.1A

N/A

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
	+T 1-4	0 1 0	
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	22 October 2018	
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 2,154,985,818	+Class
		L	İ

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

Number +Class 26,058,867 being the Number and +class of all Executive 9 total number of +securities not quoted on ASX **Performance Rights** (including the +securities in performance rights on section 2 if applicable) issue immediately prior to this 3B (25,697,140) plus the number of new performance rights (361,727)64,649,575 Senior Manager **Performance Rights** Dividend policy (in the case of a Refer to item 4 of this Appendix 3B 10 trust, distribution policy) on the increased capital (interests) Part 2 - Pro rata issue holder Is security approval No 11 required? Is the issue renounceable or non-N/A 12 renounceable? Ratio in which the *securities N/A 13 will be offered *Class of *securities to which the N/A 14 offer relates ⁺Record date to determine N/A 15 entitlements Will holdings different 16 on N/A registers (or subregisters) be aggregated for calculating entitlements? Policy for deciding entitlements 17 N/A in relation to fractions

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

30		do security holders sell entitlements in full through ker?	N/A	
31			N/A	
32	of the	do security holders dispose eir entitlements (except by nrough a broker)?	N/A	
33	⁺ Issue	e date	N/A	
		uotation of securitie	S oplying for quotation of securities	
34	Type of *securities (tick one)			
(a)		⁺ Securities described in Part 1		
(b)		All other *securities		
		Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitie	es tha	t have ticked box 34(a)		
Addit	ional	securities forming a new	v class of securities	
Tick to docume		e you are providing the informat	cion or	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders			
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000		

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

	10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	N/A	Cidss

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

ompany secretary)

Date: 02 November 2018

Print name: Greg Gettingby

== == == == ==

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue		
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period		
"A"		

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
• Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	
Step 4: Subtract "C" from ["A" x "I placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	
Note: number must be same as shown in Step 2	
Subtract "C"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10		
Note: number must be same as shown in Step 2		
Subtract "E"		
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"		
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.